Targeted Delivery System Using CD45+ Leukocyte Cells for Glioma Treatment
Summary
USPTO published patent application US20260091119A1 disclosing an isolated targeted delivery system using CD45+ leukocyte cells containing iron binding proteins complexed with therapeutic or diagnostic agents for glioma treatment. Inventors include Magdalena KRÓL and seven co-inventors. The application was filed on September 1, 2023.
What changed
USPTO published patent application US20260091119A1 for a targeted delivery system comprising CD45+ leukocyte cells loaded with a complex of iron binding proteins and a pharmaceutical or diagnostic agent for glioma treatment. The system leverages the natural tumor-homing capability of CD45+ leukocytes to deliver therapeutic payloads across the blood-brain barrier. Application No. 19110576; inventors: KRÓL, BENNI, BAIOCCO, RYGIEL, BOFFI, BIALASEK, MARSZALEK, BARTLOMIEJ (Taciak).
This is an informational patent publication with no regulatory compliance obligations. Pharmaceutical and biotechnology companies may review the published claims to assess freedom-to-operate or licensing opportunities. No action is required for regulatory compliance purposes. The patent application remains pending and does not authorize commercial sale of any product.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA
Application US20260091119A1 Kind: A1 Apr 02, 2026
Inventors
Magdalena KRÓL, Irene BENNI, Paola BAIOCCO, Tomasz RYGIEL, Alberto BOFFI, Maciej BIALASEK, Ilona MARSZALEK, Taciak BARTLOMIEJ
Abstract
The present invention relates to an isolated targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and a pharmaceutically active substance, label or pharmaceutically active substance and label, for use in a method of treatment or diagnosis of glioma.
CPC Classifications
A61K 47/64 A61K 35/15 A61P 35/00
Filing Date
2023-09-01
Application No.
19110576
Named provisions
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Therapeutics (A61P) publishes new changes.